Genprex and Roche Diagnostics launched collaboration plans to validate a biomarker assay in non-small cell lung cancer, centered on TROP2. Genprex said it expects to potentially integrate TROP2 expression into patient-selection approaches for clinical studies, while Roche will perform assay validation using its TROP2 antibody. The arrangement highlights the growing role of companion biomarker readiness as trials move forward, especially where ADC and targeted modalities depend on consistent target quantification. For sponsors, the collaboration is a practical step toward reducing variability across pathology and assay platforms that can delay enrollment or complicate trial interpretation.